

N.Meca, J. Pardo, G. Garreta, C. Sebastián, M. Iglesias, F. Salazar, J. Nicolás
Hospital Universitari Mútua Terrassa, Pharmacy, Terrassa, Spain

BACKGROUND AND IMPORTANCE


The introduction of **bitherapy** has been a great advance in antiretroviral treatment. This has made possible to obtain the same results in terms of efficacy with a smaller number of active ingredients (API), simplification of dosage, reduction of adverse effects (AE) and decrease in interactions.

AIM AND OBJECTIVES

- Describe the patient's profile, description of current bitherapy and previous treatment.
- The second objective was to study the efficacy, safety and interactions of bitherapy, as well as the reason for switch.

MATERIAL AND METHODS

Retrospective descriptive study



- ❖ **Variables were collected** (electronic medical record):
- Demographics (sex, age), comorbidities
 - Viral load (CV) and CD4 prior to change
 - CV and CD4 12 months post-switch
 - Previous antiretroviral treatment
 - Reason for change

RESULTS


104 patients

- 70,2 % ♂
- 51 years (24-84 years)



105 bitherapies

Dolutegravir/rilpivirine



Dolutegravir/lamivudine

Prior to the switch, **97,1%** of patients had **undetectable CV** (<50 copies/mL) and **CD4 levels of 750 cells/μL** (300-2720).

main pretreatment: **78,4%**
dolutegravir/rilpivirine/tenofovir-alafenamide

main pretreatment: **79,4%**
dolutegravir/lamivudine/abacavir

After 1 year post-switch, **95,2%** were **CV negative** with **CD4 levels 800 cells/μL** (354-1580)

- ❖ One episode of nervousness was collected as an **AE**.
- ❖ **No interactions** were detected.

- ❖ In **85,7%** it involved a **reduction in the number of APIs** (pre:3 vs. post:2)
- ❖ In **14,3%** a **simplification** of the regimen to a single tablet/day.




Figure 1. Main reason for therapeutic switch

CONCLUSION AND RELEVANCE

- ✓ Treatment with **dolutegravir-based bitherapies** has proven to be an effective, safe therapy with no relevant interactions.
- ✓ The **principal reason** for switching to bitherapy is **simplification**, achieving a reduction in both: the number of tablets and the number of APIs versus previous therapies.
- ✓ The **role of the pharmacist** was fundamental for **pharmaceutical care and clinical follow-up**, detection of interactions, as well as monitoring of adverse effects.